‌

Supported via arm's length funding from Gilead.

Highlights from

SABCS 2021

San Antonio Breast Cancer Symposium

San Antonio, Texas, 7 - 10 December 2021
SCROLL TO ARTICLES

    Articles

    Using genomic profiling to match treatment improves survival outcomes for certain patients with metastatic breast cancer

    Both exemestane and tamoxifen added to OFS sustain reduction in distant recurrence and death in patients with hormone receptor-positive (HR+) early breast cancer

    MONALEESA trials: overall survival in patients with HR+/ HER2- advanced breast cancer by subtype, metastasis site and more

    DESTINY-Breast03 trial: survival outcomes with T-DXd versus T-DM1 in patients with HER2+ unresectable or metastatic breast cancer

    Updated overall survival results from the phase III PHOEBE trial in HER2+ metastatic breast cancer

    Top image: rustycloud

    The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

    Supported by